French
DeutschAZD2327
 | |
| Names | |
|---|---|
| IUPAC name 4-[(R)-(3-aminophenyl)-[4-[(4-fluorophenyl)methyl]piperazin-1-yl]methyl]-N,N-diethylbenzamide | |
| Identifiers | |
PubChem CID | |
| Properties | |
| C29H35FN4O | |
| Molar mass | 474.624 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
AZD2327 is a drug used in scientific research, it is being investigated for the treatment of anxiety.
Pharmacology
[edit]AZD2327 appears to be a selective and strong agonist of the delta opioid receptor, it is also an inhibitor of CYP3A4.[1]
Anxiolytic
[edit]In a study, AZD2327 has been shown to inhibit the release of noradrenaline caused by anxiety, it was able to inhibit it as much as diazepam.[2] However, in this case, AZD2327 could be a better option than diazepam, because benzodiazepines (such as diazepam) often cause rapid tolerance and physical dependence[3], however, it seems like AZD2327 does not cause tolerance development.[2]
Another study has also concluded by mentioning that AZD2327 has potential as an anxiolytic.[4]
It is also worth noting that AZD2327 appears to have a low potential of abuse[5], unlike certain anxiolytics such as benzodiazepines which are easily abusable.
References
[edit]- ^ Guo, Jian; Zhou, Diansong; Li, Yan; Khanh, Bui H. (November 2015). "Physiologically based pharmacokinetic modeling to predict complex drug–drug interactions: a case study of AZD2327 and its metabolite, competitive and time‐dependent CYP3A inhibitors". Biopharmaceutics & Drug Disposition. 36 (8): 507–519. doi:10.1002/bdd.1962. ISSN 0142-2782.
- ^ a b Hudzik, T. J.; Maciag, C.; Smith, M. A.; Caccese, R.; Pietras, M. R.; Bui, K. H.; Coupal, M.; Adam, L.; Payza, K.; Griffin, A.; Smagin, G.; Song, D.; Swedberg, M. D. B.; Brown, W. (July 2011). "Preclinical pharmacology of AZD2327: a highly selective agonist of the δ-opioid receptor". The Journal of Pharmacology and Experimental Therapeutics. 338 (1): 195–204. doi:10.1124/jpet.111.179432. ISSN 1521-0103. PMID 21444630.
- ^ Rosenberg, Howard C.; Chiu, Ted H. (March 1985). "Time course for development of benzodiazepine tolerance and physical dependence". Neuroscience & Biobehavioral Reviews. 9 (1): 123–131. doi:10.1016/0149-7634(85)90038-7.
- ^ Richards, Erica M.; Mathews, Daniel C.; Luckenbaugh, David A.; Ionescu, Dawn F.; Machado-Vieira, Rodrigo; Niciu, Mark J.; Duncan, Wallace C.; Nolan, Neal M.; Franco-Chaves, Jose A.; Hudzik, Thomas; Maciag, Carla; Li, Shuang; Cross, Alan; Smith, Mark A.; Zarate, Carlos A. (March 2016). "A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression". Psychopharmacology. 233 (6): 1119–1130. doi:10.1007/s00213-015-4195-4. ISSN 0033-3158. PMC 5103283. PMID 26728893.
- ^ Hudzik, T.J.; Pietras, M.R.; Caccese, R.; Bui, K.H.; Yocca, F.; Paronis, C.A.; M.D.B., Swedberg (September 2014). "Effects of the δ opioid agonist AZD2327 upon operant behaviors and assessment of its potential for abuse". Pharmacology Biochemistry and Behavior. 124: 48–57. doi:10.1016/j.pbb.2014.05.009.